Announced details
Pharmaceutical manufacturing and supply
Transferring production of Steboronin® to a new contract manufacturer
The related costs have already been incorporated into the revised full-year earnings forecast for the fiscal year ending March 2026 and the planned revision of the target figures in the medium-term management plan for the fiscal year ending March 2027.
The company does not address Contract Value / Offering price.
PMDA (the Pharmaceuticals and Medical Devices Agency)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Steboronin® |
| Relationship with the Company | Transferring production of Steboronin® to a new contract manufacturer |
| Launch date | Aiming to commence full-scale manufacturing (specific start date: Not disclosed) |
| Applicable area | Pharmaceutical manufacturing and supply |
| Impact on Business Performance | The related costs have already been incorporated into the revised full-year earnings forecast for the fiscal year ending March 2026 and the planned revision of the target figures in the medium-term management plan for the fiscal year ending March 2027. |
| Source | PMDA (the Pharmaceuticals and Medical Devices Agency) |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To ensure a stable supply to the market and prevent any disruption to product supply. The transfer is being carried out based on discussions with the PMDA (Pharmaceuticals and Medical Devices Agency).